Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer (ESCC-PT)
Precision Medicine Strategies for Advanced Esophageal Cancer Refractory to Immune Checkpoint Inhibitors
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: zhihao Lu
- 전화번호: 010-88196561
- 이메일: pppeirain@126.com
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Signed written informed consent from previous studies and age ≥18 years.
- Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC).
- Locally advanced, unresectable, or metastatic ESCC that progressed on or after standard second-line or later therapy containing immunotherapy (including but not limited to PD-1, PD-L1, CTLA-4 antibodies, or bispecific antibodies).
- At least one measurable lesion per RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Anticipated life expectancy ≥12 weeks.
Adequate organ and bone marrow function within 14 days prior to the first dose (without blood transfusion, EPO, G-CSF, or other hematologic supports), as defined by:
- Absolute neutrophil count (ANC) ≥1.5×109/L
- Platelet count ≥100×109/L
- Hemoglobin ≥9 g/dL (or ≥5.6 mmol/L)
- Serum albumin >30 g/L
- Serum creatinine ≤1.5×ULN (Upper Limit of Normal) or calculated creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula)
- Total bilirubin ≤1.5×ULN
- AST and ALT ≤2.5×ULN (≤5.0×ULN for patients with documented liver metastases, provided total bilirubin is within normal limits)
- International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5×ULN, and activated Partial Thromboplastin Time (aPTT) ≤1.5×ULN
- Female patients of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to the first dose. WOCBP and male patients with WOCBP partners must agree to use highly effective contraception from signing the informed consent throughout the treatment period and for at least 6 months after the last dose. (Highly effective methods include oral/implanted hormonal contraceptives, intrauterine devices [IUDs], or barrier methods combined with spermicide. Postmenopausal women aged >50 years must have been amenorrheic for ≥12 months to be considered postmenopausal).
Required washout periods prior to the first dose of study treatment are as follows:
- Systemic anticancer therapies (chemotherapy, targeted therapy, immunotherapy, biological therapy, or hormonal therapy) or participation in clinical trials: >4 weeks.
- Systemic small-molecule targeted therapies: >2 weeks or 5 half-lives (whichever is longer).
- Prior Chinese herbal medicine with anti-tumor activity: >2 weeks.
- Prior major surgery or radiotherapy: >4 weeks (palliative radiotherapy for bone metastases: >2 weeks).
Exclusion Criteria:
Exclusion Criteria
- Currently receiving concurrent antitumor therapies (including chemotherapy, systemic therapy, immunotherapy, radiotherapy, or surgery) at the time of enrollment.
- History of other malignancies within the past 3 years (except for cured thyroid cancer, cervical carcinoma in situ, basal/squamous cell skin cancer, or other cured localized tumors with disease-free survival >3 years).
- Adverse events (AEs) from prior antitumor therapies that have not resolved to baseline or Grade ≤1 (excluding alopecia, Grade 2 anemia, or irreversible, clinically insignificant, asymptomatic laboratory abnormalities).
- Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose, or not fully recovered from surgical procedures; or plans for surgery during the study period.
- Active peripheral neuropathy (PN) or neurotoxicity ≥ Grade 2, history of Grade 3 neurotoxicity/PN, or prior permanent discontinuation of treatment due to neurotoxicity/PN.
- Active pneumonitis/interstitial lung disease (ILD), history of pulmonary radiation within 12 months prior to the first dose, or clinically significant underlying pulmonary disease (e.g., chronic obstructive pulmonary disease).
- Symptomatic or active central nervous system (CNS) metastases requiring intervention (including steroid therapy with prednisone >10 mg/day or equivalents, or anticonvulsants) within 4 weeks prior to the first dose.
- Any other severe underlying medical condition, including but not limited to: uncontrolled diabetes, active infections, vaccination within 4 weeks, active peptic ulcer, uncontrolled epilepsy, cerebrovascular accident within 6 months, gastrointestinal bleeding within 3 months, or clinical signs of coagulopathy.
Clinically significant cardiovascular disease, including:
- Left ventricular ejection fraction (LVEF) ≤50% or below the institutional lower limit of normal (LLN) determined by echocardiography (ECHO) or MUGA scan (if ECHO is unavailable).
- Heart failure classified as NYHA Class ≥III.
- Uncontrolled hypertension (systolic BP ≥150 mmHg and/or diastolic BP ≥95 mmHg despite optimal medical therapy).
- Prior or current cardiomyopathy.
- Unstable angina, or myocardial infarction within 6 months.
- Serious arrhythmia requiring medical intervention (excluding controlled atrial fibrillation or paroxysmal supraventricular tachycardia).
- QTc interval ≥450 ms for males, or ≥470 ms for females (using Fridericia's formula), or history of congenital long QT syndrome.
- Dyspnea due to advanced malignancy complications or other diseases, requiring continuous supplemental oxygen therapy at rest.
- Any other severe psychiatric, psychological, familial, or geographical conditions that, in the investigator's opinion, could interfere with study compliance, protocol execution, follow-up, or place the patient at high risk of treatment-related complications.
- History of HIV infection or positive HIV serology.
- Active viral hepatitis B or C (Note: Patients with HBV are eligible if HBV DNA is within the normal range/suppressed on antivirals; patients with positive HCV antibody are eligible if HCV RNA is undetectable via PCR). Frequent viral load monitoring is mandatory.
- History of life-threatening allergies, known hypersensitivity to any study drug components, recombinant proteins, or excipients, or intolerance to EGFR antibodies or eribulin.
- Pregnant or lactating women.
- Any concurrent medical condition that, in the investigator's clinical judgment, could compromise protocol compliance.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: EGFR High Expression or Pathway Activation
This treatment arm comprises patients with advanced esophageal squamous cell carcinoma (ESCC) who have progressed on prior immunotherapy and exhibit high EGFR expression or activation of EGFR-related signaling pathways determined by ctDNA sequencing.
|
Patients in this cohort will receive Afatinib at a dose of 40 mg orally (p.o.) once daily (Q.D.) combined with Toripalimab at a dose of 240 mg intravenously (i.v.) every 3 weeks (Q21D).
Treatment will continue in 21-day cycles until radiographic disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met.
Toripalimab administration is capped at a maximum duration of 24 months.
|
|
실험적: Cell Cycle Pathway Alteration
This treatment arm comprises patients with advanced ESCC refractory to prior immunotherapy harboring genomic alterations directly associated with cell cycle regulation or activation of cell cycle signaling pathways based on ctDNA profiling.
|
Patients will receive Dalpiciclib at a dose of 125 mg p.o. Q.D. for 21 consecutive days followed by a 7-day off period in a 28-day cycle (Q4W), in combination with Pyrotinib maleate at a dose of 320 mg p.o. Q.D. administered within 30 minutes post-meal (Q4W).
Treatment will continue until disease progression, unacceptable toxicity, initiation of a new anti-tumor therapy, or withdrawal of consent.
|
|
실험적: Other Molecular Subtypes
This treatment arm comprises patients with advanced ESCC refractory to prior immunotherapy whose tumors present other molecular profiles not meeting the criteria for Cohorts 1 or 2.
|
Patients in this cohort will receive a triple-combination therapy consisting of Camrelizumab (200 mg i.v.
every 3 weeks [Q3W]), and Apatinib (250 mg p.o. Q.D.).
Efficacy evaluations will be performed every 6 weeks.
Treatment will continue until radiographic disease progression, unacceptable toxicity, death, or treatment discontinuation, whichever occurs first.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
무 진행 생존 (PFS)
기간: 1 년
|
무 진행 생존 (PFS)은 Recist v1.1 당 첫 번째 용량에서 첫 번째 문서화 된 질병 진행 또는 임의의 원인으로부터의 사망으로 정의되었다.
|
1 년
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
전체 생존 (OS)
기간: 1 년
|
전체 생존 (OS)은 모든 원인으로부터 첫 번째 복용량에서 사망 시간으로 정의됩니다.
|
1 년
|
|
Objective Response Rate (ORR)
기간: 1 year
|
Objective Response Rate (ORR) as assessed by RECIST v1.1
|
1 year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ESCC-PT
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .